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Abstract
This paper is a proposal for an update on the characterization of cognitive impair-
ments associatedwith sporadic cerebral small vessel disease (SVD).Wepose a series of
questions about the nature of SVD-related cognitive impairments andprovide answers
based on a comprehensive reviewandmeta-analysis of published data from69 studies.
Although SVD is thought primarily to affect executive function and processing speed,
we hypothesize that SVDaffects all major domains of cognitive ability.We also identify
low levels of education as a potentiallymodifiable risk factor for SVD-related cognitive
impairment. Therefore, we propose the use of comprehensive cognitive assessments
and the measurement of educational level both in clinics and research settings, and
suggest several recommendations for future research.
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1 CONTEXT FOR THE “HYPOTHESIS”
The termsmall vessel disease (SVD) refers to a collectionof neuroimag-
ing and neuropathological abnormalities found in the brain’s white and
deep gray matter. Visible radiological markers of the disease include
white matter hyperintensities (WMH) and lacunes of presumed vascu-
lar origin, cerebral microbleeds, visible perivascular spaces, and cere-
bral microinfarcts. These markers likely reflect multiple pathological
changes affecting the brain’s small vessels, such as endothelial dys-
function, impaired cerebral blood flow, and reduced vessel pulsatility,
although the relationships among these mechanisms are complex and
not yet fully understood.1,2 SVD is the primary cause of vascular cog-
nitive impairment (VCI) in older age. The meaning of the term VCI has
been refocused several times in recent years,3-5 but broadly refers to
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cognitive impairments due to underlying vascular contributions, which
can range in severity from subtle subclinical decline in cognitive ability,
to mild cognitive impairment (MCI) and dementia.7,8 In this review, we
use the term “impairment” to denote any reduction in cognitive abil-
ity relative to an individual’s typical ability, as opposed to a normative
standard, or a diagnostic construct, unless otherwise stated.
1.1 Why is SVD-related cognitive impairment
important?
As life expectancies across the world continue to rise, so too does the
predicted global burden of age-related cognitive impairment, includ-
ing VCI. In all societies, the economic impact of cognitive impairment
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is tremendous. Individuals with cognitive impairment usemore health-
care services and require greater support with activities of daily liv-
ing, either from unpaid family carers, or from paid care services.9,10 In
2002, a review of the costs associated with VCI in Canada estimated
the average annual cost per individual to be between CAD $15,022
(USD equivalent $9,313) for mild VCI, and CAD $34,515 (USD equiv-
alent $21,399) for severe VCI.10 Equally as striking is the personal
impact upon individuals experiencing cognitive impairment, who are at
greater risk of anxiety and depression and report having a lower qual-
ity of life.11,12 A reduction in the incidence or progression of cognitive
impairment, therefore, is a key target for clinical trials of treatments or
interventions for SVD. Any intervention that improves cognitive out-
comes in SVD has the potential to alleviate the burdens it places on
individuals and on our societies, and would be a step toward reducing
rates of VCI andmultiple major dementias.
1.2 What kind of cognitive impairments are
associated with SVD?
To accurately assess cognitive ability in SVD and how it might change
in response to intervention, researchers must use cognitive tests that
are sensitive to the cognitive impairments caused by SVD. However,
despite a hugenumber of studies on the subject, the nature of cognitive
impairments in SVD remains poorly characterized. Current consensus
statements suggest that the disease primarily affects the domains of
processing speed and executive function, but that memory and lan-
guage abilities remain relatively well preserved.13,14 Processing speed
refers to the speed at which a person can understand and respond
to information.15 Executive function is a broader concept encompass-
ing skills such as planning, organization, and switching attention, which
enable goal-directed behaviors.15 This profile of SVD-related cognitive
impairments is frequently reported in the research literature, but the
studies underpinning this suggestion are conflicting and require careful
consideration. First, many of the studies examining SVD-related cog-
nitive impairments have small participant samples, so could be insuf-
ficiently powered to detect cognitive deficits. Second, many of these
studies focus on narrowly defined subtypes of SVD (ie, genetic SVDs),
or on those with a high disease burden who may not represent the
full spectrum of sporadic SVDs. We also anticipate that some studies
may be influenced by expectations of the cognitive impairments they
will observe. Based on the understanding that SVD causes deficits in
executive function and processing speed, studies might carry out tests
that measure only those abilities and neglect to test for impairments
in other abilities such as memory, which are more typically associated
with dementia.
To gain an unbiased overviewof the nature of cognitive impairments
associated with SVD, we carried out a systematic review and meta-
analysis of studies reporting cognitive data for cohorts with clinical or
radiological evidence of SVD, and control cohorts without SVD (see
Figure 1; full details of the Methods and Results are provided in Sec-
tion 2). As expected, the sample sizes of the SVD cohorts were small,
ranging between 4 and 196 participants (median: 27). Four studies
RESEARCH INCONTEXT
1. Systematic review:We conducted systematic searches of
MEDLINE, Embase, and PsycINFO. Identified literature
contradicts current consensus statements on small ves-
sel disease (SVD)–related cognitive impairments, which
describe impaired information processing speed and
executive functions, alongside preserved memory and
language skills. Also, little is known about whether cog-
nitive impairments vary between clinical presentations of
SVD.
2. Interpretation: SVD-related cognitive impairments are
global, affecting all cognitive domains examined. Global
impairments were present regardless of SVD presenta-
tion (eg, stroke, mild cognitive impairment/dementia, or
non-clinical cohorts). Our findings also highlight low lev-
els of education as a potentially modifiable risk factor for
SVD-related cognitive impairments.
3. Future directions: Future studies should test a broad
range of cognitive domains, account for educational expe-
rience, and include multiple presentations of SVD, to
examine vascular contributions to cognitive impairments
and dementia.
conducted power calculations,52,57,71,85 but only one of these stud-
ies included a sample size sufficient to detect differences in cognitive
performance between groups, according to their own calculations.57
We carried out seven separate meta-analyses to examine differences
in performance between SVD and control groups in seven cognitive
domains: executive function, delayed memory, processing speed, lan-
guage, visuospatial ability, reasoning, and attention. The results of our
meta-analyses suggested that individuals with SVD performed more
poorly than controls on cognitive tests in each cognitive domain that
we examined. Our findings concurwith those of a recentmeta-analysis
of 27 studies by Vasquez and Zakzanis,16 which compared the cogni-
tive abilities of participants with vascular cognitive impairment with-
out dementia and control subjects, finding deficits in a similarly broad
range of domains. Contrary to current consensus, our results suggest
that the cognitive impairments associated with SVD extend beyond
executive function and processing speed, to affect all major domains of
cognitive ability.
Typically, multiple cognitive abilities are recruited to carry out an
individual cognitive task. For example, a list learning task is broadly
considered to be a test ofmemory, but performance of the taskwill also
require language abilities to comprehend the words on the list, pro-
cessing speed to process the verbal information, and so on. Therefore,
deficits in a number of cognitive domains could result in poor perfor-
mance on this memory task. Many cognitive tasks appear to require
speed of information processing for efficient performance, and tests
of processing speed are among those most affected by aging. As a
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F IGURE 1 Flow diagram of systematic review screening process
result, it has been suggested that processing speed drives age-related
changes in other fluid cognitive abilities.17 Moreover, processing speed
has been found to mediate, statistically, the association between brain
white matter health and general cognitive ability in older people.18
However, there is currently a more agnostic attitude to the place of
processing speed; there is not considered to be definitive evidence
about whether processing is the driver of age-related declines in other
cognitive abilities, or whether it is just another domain of cognitive
ability that declines on average with age.19,20 Whereas the results of
our meta-analyses suggest that relative to controls, cohorts with SVD
have deficits in all major domains of cognitive ability, it remains to be
examinedwhether these deficits could be the result of the early impair-
ment of certain key domains of cognitive ability, or could be the
result of impairment across multiple domains of cognitive ability more
generally.
Growing evidence suggests that SVD-related cognitive impairments
result from the disruption of white matter tract networks connecting
regions of the brain that are critical for cognitive function.21,22 Sev-
eral cohort studies have suggested that the dysexecutive/slowed infor-
mation processing profile typically associated with SVD could arise
from strategic lesions that disrupt frontal-subcortical white matter
projections, such as the anterior thalamic radiation and the forceps
4 HAMILTON ET AL.
minor.23–26 However, visible infarcts represent only a proportion of
the structural changes occurring in SVD.Microstructural alterations in
WMH extend beyond the visible lesion, into the surrounding, normal-
appearing peri-lesional tissue known as the “SVD penumbra”.27 Sim-
ilarly, the impact of visible lesions can extend beyond local tissue, to
affect distant brain regions.28 Therefore, SVD-related structural brain
changes arediffuse and likely affectwhitematter networks throughout
the whole brain.22,29 One analytic approach that has provided insight
into the impact of SVD on the structural connectivity of the brain
is the application of graph theoretic approaches to diffusion tensor
imaging (DTI) tractography data.Whereas several studies adopting this
approach have found reduced connectivity and efficiency of both local
andglobalwhitematter networks, associations between these changes
and impairments in specific cognitive domains remain unclear.22
1.3 Do cognitive impairments vary according to
the clinical presentation of SVD?
In the majority of cases, SVD manifests sub-clinically with few overt
symptoms. However, SVD also contributes to, and in some cases is
the primary cause of, a spectrum of disorders ranging from stroke, to
MCI, and multiple major dementias. SVD causes ≈20% of all strokes,
increases the risk of recurrent ischemic stroke, and associates with
poorer functional outcomes post-stroke.30,31 SVD also contributes to
≈40% of all dementias and increases the odds of developing inci-
dent dementia.32,33 Whereas stroke and dementia are often consid-
ered separately, they convey mutual risk to one another. For exam-
ple, stroke doubles the chance of developing dementia,34 and poor
cognitive performance increases the risk of stroke.35 Additionally,
increasing evidence supports the hypothesis that stroke and demen-
tia share underlying mechanisms.36,37 For example, dysfunction of the
blood–brain barrier (BBB) has been identified as one of the earliest
detectable mechanistic changes in the preclinical stages of demen-
tia, occurring prior to the development and accumulation of typical
Alzheimer’s disease (AD) biomarkers such as amyloid beta (Aβ) and
phosphorylated tau.38 Arterial stiffness, another pathological hallmark
of SVD, has also been associatedwith the deposition of Aβ and its accu-
mulation over time.39 Vascular pathologies are now considered to con-
tribute substantially to the cognitive deficits observed in most major
forms of dementia, including AD. In a recent study examining carriers
of the E4 variant of apolipoprotein E (APOE4), the primary suscepti-
bility gene for AD, BBB breakdown in the hippocampus and parahip-
pocampal gyrus was associated with poorer cognitive ability indepen-
dently of Aβ or tau accumulation.40 Whereas these findings have yet
to be replicated, they suggest that this gene variant might contribute
to AD and its resultant cognitive decline through BBB dysfunction,
rather than solely through more traditional AD biomarkers. In 2017
the World Health Organization highlighted the prevention of stroke
via the management of traditional vascular risk factors (eg, smoking,
high blood pressure, high cholesterol, diabetes) as a means of prevent-
ing dementia.6 However, despite increasing recognition of cerebrovas-
cular contributions to neurodegenerative disease processes,41 little is
known about how cognitive impairments might differ across differ-
ent SVD presentations. Patients who experience stroke and dementia
have differing routes into clinical care, are treated by different special-
ists, and are recruited into different research studies, often preventing
direct comparison of their cognitive symptoms.
We categorized the SVD cohorts in our sample into three groups
based on the clinical characterizations and recruitment settings
detailed in the original publications. These three groups included:
(1) non-clinical SVD cohorts (cohorts who exhibited radiological evi-
dence of SVD, but had no specific clinical or cognitive symptoma-
tology); (2) cohorts who presented with stroke; and (3) cohorts with
subjective or objective cognitive impairments, or dementia (further
detail on cohort categorization is provided in Section 2). To some
extent, our three SVD presentation categories may represent a con-
tinuum; individuals with radiological evidence of SVD but no overt
clinical symptoms may go on to experience stroke and/or dementia.
Additionally, owing to the inter-related nature of stroke and demen-
tia, it is possible that cohorts in these three categories exhibit both
vascular and neurodegenerative pathologies. As expected, tests of pro-
cessing speed, executive function, attention, and reasoning were most
frequently carried out in cohortswith stroke and tests of delayedmem-
ory, visuospatial ability and language were most commonly carried
out in cohorts with cognitive impairments (see File S1 in supporting
information).
The results of meta-regression models investigating differences in
cognitive performance of the three SVD presentation groups (relative
to controls) indicated differences in the magnitude of cognitive effect
sizes among the three groups, such that cohorts with cognitive impair-
ment/dementia performed worse than non-clinical cohorts on tests of
executive function, delayedmemory, andvisuospatial ability, andworse
than stroke cohorts on tests of delayedmemory only. It is possible that
the inclusionof sampleswith cognitive impairments (includingMCI and
dementia) could be driving the findings that SVD cohorts overall per-
formed more poorly on tests of memory than control cohorts. How-
ever, visual inspection of a forest plot for memory (Figure 2) suggests
that this is unlikely to be the case as almost all cohorts in each presen-
tation group show deficits relative to control cohorts.
1.4 How do risk factors for SVD affect cognitive
impairment?
Age is the primary risk factor for the development and progression
of SVD. The prevalence of magnetic resonance imaging (MRI) mark-
ers of SVD increase with age and are found in the majority of individ-
uals over the age of 60. In contrast, it is unclear whether biological sex
may act as a risk factor for SVD,42,43 although the under-recruitment
of women in stroke research may limit knowledge,44 and the lack of
sex-disaggregated reporting limits the scope of meta-analyses on this
topic. Owing to their potential for modification, traditional vascular
risk factors (VRFs) such as hypertension, diabetes, and hypercholes-
terolemia have received a great deal of attention, alongside lifestyle
factors such as smoking, lack of exercise, poor diet, and high salt intake.
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F IGURE 2 Forest plot of meta-analysis of tests of delayedmemory. The effect size metric is a standardizedmean difference. The sizes of the
squares reflect the weight given to each effect size. Letters in brackets indicate different SVD cohorts in a given study
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Each has been associated with increased SVD risk, but trials of risk-
lowering interventions have produced mixed results.1 Additionally, a
recent meta-analysis of early life risk factors for SVD found lower
childhood socioeconomic status, lower childhood IQ, and fewer years
of education to be associated with increased radiological burden of
SVD,45 although these risk factors are related to one another and may
convey interdependent effects.
Due to their associations with an increased brain burden of SVD,
each of these risk factors has the potential to impact cognitive ability.
Therefore, it is important that these factors are accounted for statisti-
cally (where appropriate) and considered carefully when interpreting
study results. Of the studies included in our meta-analysis, almost all
reported data on the age, sex, and education of study cohorts, how-
ever, reporting of vascular risk data was less complete (see File S2 in
supporting information). Approximately half of all studies reported his-
tory of hypertension or diabetes, and only one third of studies reported
smoking status, despite its known association with SVD progression.
Vascular risk data were least often reported for cohorts with a cogni-
tive presentation of SVD, which could suggest that these factors are
percieved as being less relevant to cohorts withMCI or dementia.
We carried out further meta-regression analyses to investigate
whether differences in age, education, or the prevalence of hyper-
tension or diabetes between SVD and control cohorts accounted for
the cognitive effects we observed in our meta-analyses. The results of
these analyses suggest that differences in years of education between
SVD and control groups account for a proportion of the differences
in cognitive test scores in the domains of memory, executive function,
and visuospatial ability. All other cognitive domains showed a simi-
lar direction of effect (albeit non-significant) except processing speed,
which could support the suggestion that processing speed might be
less amenable to beneficial effects of education than other cognitive
abilities.46 These findings highlight education as a (potentially modi-
fiable) risk factor for SVD-related cognitive impairment, emphasizing
the importance of accounting for education in analyses of cognitive
change over time, or comparisons of cognitive ability between groups.
An additional factor for consideration that is closely related to educa-
tional level is peak (or premorbid) cognitive ability. In any analysis of
cognitive decline, observed levels of cognitive ability will be relative
to an individual’s prior abilities.47 Despite this, peak cognitive ability
is seldom considered in clinical studies. Of the 69 studies included in
our meta-analysis, only seven52,56,57,64,66,92 estimated peak ability and
only two of these studies included this score as a covariate in their
analyses.56,92
1.5 Summary of findings and recommendations
for future work
Based on 3229 individuals with SVD and 3679 control participants
from 69 studies, our meta-analyses demonstrated that SVD-related
cognitive impairments affect all major domains of cognitive ability. To
accurately assess the full extent of SVD-related cognitive impairments,
we recommend the use of comprehensive test batteries that cover a
rangeof cognitive domains, such as that proposedby theNational Insti-
tute for Neurological Disorders and Stroke (NINDS) and the Canadian
Stroke Network (CSN48). This test protocol is designed for use with
participants with VCI and assesses a broad range of cognitive abili-
ties. The full-length protocol takes 60 minutes to administer, but can
be shortened to 30 or 5minutes, while still capturing information from
a fairly broad range of cognitive abilities. Widespread use of a stan-
dard cognitive testing protocol will also facilitate more accurate cross-
comparison ormeta-analysis of cognitive data from different studies.
The majority of studies in our meta-analysis had small sample sizes,
and very few studies carried out power calculations. To make infer-
ences about cognitive impairments in SVD, it is of vital importance
that studies are adequately powered to detect cognitive effects. This
meta-analysis summarizes 69 publications on a broad range of SVD
presentations—references 52 to 120 provide a useful database of
effect sizes, which can be consulted and used to estimate power cal-
culations in future studies.
The results of our first meta-regression analysis suggested that
cohorts with a cognitive presentation of SVD performed more poorly
than cohorts with non-clinical presentations of the disease on tests
of delayed memory, executive function, and visuospatial ability, and
more poorly than cohortswith stroke presentations on tests of delayed
memory. Our grouping of cohorts into their respective SVD presenta-
tion categorieswas based on cohort descriptions, recruitment settings,
and diagnostic criteria, all of which varied considerably between stud-
ies. A more effective approach to characterizing SVD subtypes would
be to recruit subjectswith differing presentations of SVD into the same
study, whichwould facilitate comparison of cognitive and other clinical
outcomes.
As we have described, vascular disease and neurodegeneration are
interrelated. Where possible, data should be collected that is relevant
to both vascular and neurodegenerative disease processes. In terms of
cognitive data, this would mean collecting data from a broad range of
cognitive domains, as previously recommended. In terms of neuroradi-
ological data, this wouldmean considering radiological markers of SVD
(WMH, enlarged perivascular spaces, lacunes, microbleeds, microin-
farcts, altered diffusion tensor imaging metrics), and those more com-
monly associated with neurodegeneration such as cerebral atrophy
and hippocampal volume. The collection of vascular risk data is also
important. History of hypertension, diabetes, and smoking status are
quick to ascertain and should be collected for all individuals with sus-
pected SVD in clinical and research settings. The collection of vas-
cular biomarkers at different stages throughout the development of
dementia may also provide an indication of the changing contributions
of vascular dysfunction to neurodegenerative disease processes over
time. Through a more complete exploration of the risk factors, brain
changes, and cognitive consequences that are shared between stroke
and dementia, more accurate characterization of SVD subtypes and
their precipitating factors might be possible.
Finally, the results of our second set of meta-regression analyses
indicated that level of education is associatedwith the severity of SVD-
related cognitive impairments. We strongly recommend that future
studies account for educational level or peak cognitive ability when
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examining cognitive change over time, or comparing cognitive ability
between groups. A range ofmethods can be used to estimate peak cog-
nitive ability, someofwhichare freeandhavebeenvalidated inmultiple
languages.49
2 APPENDIX
2.1 Methods
Weperformed this systematic review andmeta-analysis in accordance
with PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines. The review protocol is registered on the
PROSPERO database (ID: CRD42017080215).
2.1.1 Search strategy and study selection criteria
Wedeveloped and tested a detailed search strategy (see File S3 in sup-
porting information) to identify studies reporting the results of cogni-
tive testing in a cohort with SVD (performed contemporaneous with
identification of SVD), and a control cohortwith nohistory of neurolog-
ical or psychiatric conditions. We searched OVID MEDLINE, Embase,
and PsycINFO, for human studies published in any language from
January 1, 1985, when MRI became more widely available in clinical
practice, toOctober 6, 2019. To identify additional studies, we checked
the reference lists of relevant review articles and hand-searched the
previous 7 years of Stroke and the Journal of Cerebral Blood Flow and
Metabolism. Study inclusion and exclusion criteria are presented in File
S4 in supporting information.
2.1.2 Data extraction
Two authors (OH and EB) independently extracted key information,
which included group-level demographic data for the SVD and con-
trol groups (age, sex, education), group-level data on vascular risk fac-
tors (% cohorts with hypertension, diabetes, hypercholesterolemia,
and smoking status), group-level data on WMH burden, and group-
level cognitive test scores for SVD and control groups. The vast major-
ity of cognitive data were presented as mean and standard deviation.
To avoid introducing additional heterogeneity into the meta-analysis
dataset, we did not convert cognitive data presented as median and
range to mean and standard deviation—instead these data are sum-
marized in File S5 in supporting information. Where individual par-
ticipant data were presented, we calculated the mean and standard
deviation of the variables we extracted. Cognitive data were then cat-
egorized into seven domains of cognitive ability: information process-
ing speed, executive function, delayed memory, attention, reasoning,
visuospatial ability, and language. However, it is important to note that
subdomains of cognitive ability are not discrete, and that individual
cognitive tests often engage abilities from multiple cognitive domains.
To ensure that tests were reliably categorized according to the
cognitive domain that they are considered to primarily assess, two
authors experienced in neuropsychological testing (OH and AJ) inde-
pendently categorized cognitive data into the seven domains listed
above and resolved disagreements by consensus (see File S6 in sup-
porting information for further information). Studies reported a wide
range of memory tests, including tests of long-term, short-term, and
working memory. To reduce heterogeneity in the dataset, we included
only tasks featuring a delayed recall/recognition component, as these
were the most frequently reported memory tasks. We excluded data
for which we could not identify the specific test score (eg, where
authors reported results for a Trail Making task, but did not specify
whether the score was for Trail Making A, Trail Making B, or Trail Mak-
ingA-B).Wealso excludeddata forwhichwecould not discernwhether
a higher or lower score indicated better performance. Where studies
reported multiple scores for one cognitive test (eg, for the Wiscon-
sin Card Sorting Test: number of perseverative errors, total number of
errors, number of categories, etc.), we included the score most com-
monly reported in the meta-analysis dataset. Due to the large number
of included studies and the large number of variables used in our analy-
ses (ie, sociodemographic, cognitive, andvascular risk variables),wedid
not contact the authors of original publications to obtain missing data.
2.1.3 Statistical analysis
We calculated a standardized mean difference (SMD) to represent the
difference between performance of the SVD and control cohorts on
each cognitive test. We multiplied the SMD by –1 for tests on which a
lower score indicated better performance. We excluded three studies
due to reporting of implausibly large effect sizes, which upon examina-
tion appeared to be due to statistical or reporting errors in the original
publications. While several larger effect sizes (SMD > 3) remain in our
meta-analyses, these effect sizes come from small study samples so are
unlikely to affect results if omitted.
2.1.4 Meta-analysis models
We ran seven separate random effectsmeta-analyses to assess the dif-
ferences in performance between SVD and control groups on cogni-
tive tests in each cognitive domain. We conducted all meta-analyses
using the robumeta package50 in R version 3.6.1.51 robumeta permits
the meta-analysis of multiple effect sizes from one study using robust
variance estimation (RVE) to account for their statistical dependency.
This approach maximizes the amount of data included from a single
study, increasing the statistical power of each meta-analysis. Depen-
dency in our dataset arose from the inclusion of multiple effect sizes
from the same study sample, and the inclusion of studies that used the
same control group as a comparison for multiple SVD groups. Covari-
ance matrices for multiple outcomes arising from a single study are
rarely published; therefore, robumeta imputes a user-specified value
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for the within-study effect size correlation. We were conservative in
our choice of within-study effect size correlation—we specified rho
as 0.8 and carried out sensitivity analyses in robumeta, which impute
rho values at increments of 0.1 to test whether this alters the model
results. For all analyses, we weighted effect sizes according to a corre-
lated effects dependence structure within the robumeta package and
used small sample size corrections. Small sample corrections, which
correct both the residuals and degrees of freedom (df) used in the RVE,
increase the accuracy of models including<40 studies.50 After correc-
tion, if the Satterthwaite df for themodel are less than four, the P value
is considered unreliable due to the probability of type I error being
greater than 0.05. In our analyses, results ofmodelswith Satterthwaite
df < 4 were considered unreliable. We report I2 and τ2 as measures of
heterogeneity.
2.1.5 Meta-regression models
Wecarriedout twosecondary analyses toexamine the following study-
level and cohort-level variables:
1 SVD presentation
To test whether the pooled study effect size differed according to
SVDpresentation, we grouped each SVD cohort into one of three cate-
gories according to the characterization of the cohort and recruitment
setting detailed in the original publication (see File S7 in supporting
information).
a) Stroke presentations
Cohorts in this categorymost commonlypresented to strokeorneu-
rology services with symptoms of lacunar syndrome, with or without
evidence of corresponding vascular lesions. Other cohorts in this cate-
gory had radiologically identified SVD, or subcortical ischemic vascular
disease.
b) Cognitive presentations
Cohorts in this category were identified on the basis of impaired
cognitive ability ranging from MCI to vascular dementia. Typically,
cohorts presented with cognitive impairment (according to clinical
diagnosis, objective cognitive testing, or subjective concern) and either
radiological evidence supporting a vascular etiology, or multiple risk
factors for cerebrovascular disease.
c) Non-clinical presentations
Non-clinical cohorts had radiological evidence of SVD (WMH or
lacunesof presumedvascular origin), but noclinical diagnosis. Typically,
cohorts were community-dwelling older individuals recruited within
a defined geographical region, or via community advertising. Several
cohorts in this category presented to clinical serviceswith non-specific
symptoms such as dizziness or headache, but received no diagnosis
upon examination.
We then entered SVD presentation as an ordinal predictor in the
meta-regression model for each cognitive domain, with the cognitive
presentation category as the reference group.
2 Differences in the prevalence of vascular risk between the SVD and
control cohorts
All extracted cognitive data were unadjusted for demographic or
vascular risk factors. Therefore, to testwhetherdifferences in age, edu-
cation, hypertension, or diabetes between SVD and control cohorts
accounted for study effect sizes, we calculated the difference in age,
years of education,% samplewithhypertension, and%samplewithdia-
betes (eg, difference in age=mean age of control cohort –mean age of
SVD cohort), and entered these variables as predictors in separate uni-
variate meta-regressionmodels for each cognitive domain.
2.1.6 Quality assessment
Quality assessment criteria (see File S8 in supporting information)
were devised according to STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology) guidelines. Two authors (OH
and EJ) independently assessed the quality of included publications on
a scale ranging from 0 to 8 and resolved disagreements by consensus.
To assess whether the inclusion of lower quality studies affected the
results of the meta-analyses, we re-ran meta-analysis models exclud-
ing studies with quality scores lower than the median quality score of
themeta-analysis sample.
2.2 Results
We identified 69 studies for inclusion in the review52-120 (see Table 1)),
which reported data for 89 cohorts with SVD (n = 3229), and 71
control cohorts (n = 3679; demographic data for the SVD and con-
trol cohorts are presented in Table 2). We did not pre-select liter-
ature that focused on a certain lesion type, or clinical, cognitive, or
behavioral presentation of SVD, therefore, our dataset included SVD
cohorts recruited from specialized cerebrovascular clinics; memory
clinics; hospital-based stroke, dementia, and general neurology ser-
vices; non-specialist medical centers; a stroke research network; and
also included several research cohorts of healthy community-dwelling
individuals. Included studies were from 18 countries in six continents,
published in four languages.
2.2.1 Meta-analyses
The pooled estimated effect size for each meta-analysis demonstrated
that on average, control cohorts outperformed SVD cohorts on cog-
nitive tasks in every domain examined (see Table 3 and forest plots in
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TABLE 2 Summary of sociodemographic and vascular risk data for SVD and control cohorts
SVD cohorts Control cohorts
Cohorts
(n= 89)
Mean (SD or
95%CI)
Cohorts
(n= 71)
Mean (SD or
95%CI)
Mean agea 88 69.3 (67.8, 70.9) 70 66.4 (64.6, 68.2)
% female 76 49.0 (15.9) 63 50.9 (15.0)
Mean years educationa 67 10.3 (9.7, 10.9) 53 10.8 (10.1, 11.6)
% hypertension 48 66.7 (23.0) 34 37.8 (20.7)
% diabetes 45 25.5 (13.7) 31 17.1 (13.5)
% hypercholesterolemia 5 55.1 (20.0) 4 35.1 (12.3)
% history of smoking 28 28.3 (16.1) 16 25.6 (16.9)
aMean age and mean years of education were calculated using random effects meta-analysis in the meta package in R version 3.6.1.121 Only studies that
presented group-level data for age and years of education as mean and standard deviation were included in these meta-analyses. We did not test for differ-
ences in age, sex, level of education, or vascular risk factors between the SVD and control groups as some studies only reported these data for the SVD group,
therefore, comparisons would not include all participants contributing cognitive data to themeta-analyses.
Abbreviations: CI, confidence interval; SD, standard deviation; SVD, cerebral small vessel disease.
TABLE 3 Results of meta-analysis models for each cognitive domain
Heterogeneity
Studies Outcomes Estimate (SE) 95%CI
Degrees of
freedom
Uncorrected
p value τ2 I2
Processing speed 37 88 –0.885 (0.14) –1.17, –0.60 35.8 2.3× 10−7 0.6 91.4
Executive function 58 188 –0.936 (0.08) –1.09, –0.78 56.1 <2× 10−16 0.4 87.6
Delayedmemory 41 98 –0.898 (0.10) –1.10, –0.69 39.6 7.2× 10−11 0.5 88.0
Attention 12 19 –0.622 (0.14) –0.94, –0.31 10.6 0.001 0.2 80.8
Reasoning 16 25 –0.634 (0.14) –0.93, –0.34 14.6 4.2× 10−4 0.2 76.5
Visuospatial ability 27 50 –0.720 (0.11) –0.96, –0.48 25.3 1.3× 10−6 0.3 77.6
Language 24 42 –0.808 (0.10) –1.01, –0.60 22.7 3.2× 10−8 0.3 81.2
Abbreviations: CI, confidence interval; SE, standard error.
Figure 2 and Figures S1–S6 in supporting information). I2 values, which
are an indicator of inconsistency between effect sizes in the meta-
analyses, were high in eachmodel.
2.2.2 Meta-regression analyses
Our meta-analysis dataset included 26 cohorts with stroke presenta-
tions of SVD, 31 cohorts with cognitive impairment or dementia, and
32 cohorts with non-clinical presentations of SVD. There were no
differences in years of education, or prevalence of hypertension or
diabetes among the three SVD presentation categories, but cohorts
with cognitive impairment/dementia were significantly older than
those with non-clinical presentations of the disease (P = .002; see
Table 4).
Meta-regressionmodels investigatingdifferences in cognitive effect
sizes of the three SVD presentation groups indicated that the effect
size for delayed memory was 0.83 standard deviations greater for the
stroke cohorts (95% confidence interval [CI]: 0.44, 1.21; P < .001) and
0.85 standard deviations greater for non-clinical cohorts (95%CI: 0.40,
1.29; P = .001), than cohorts with cognitive impairment/dementia. We
also found that the effect size was 0.49 standard deviations greater in
the domain of executive function (95% CI: 0.10, 0.88; P = .015), and
0.68 standard deviations greater in the domain of visuospatial abil-
ity (95% CI: 0.30, 1.01; P = .002) for the non-clinical cohorts than the
cohorts with cognitive impairment/dementia (see File S9 in supporting
information for full results). Including SVD presentation as a predictor
in meta-regressionmodels had little effect on study heterogeneity.
Meta-regression models investigating the impact of differences in
age, education, and the prevalence of vascular risk factors between
SVD versus control groups on cognitive effect sizes, indicated that the
difference in cognitive performance between SVD and control groups
could bedue to lower levels of education in SVDcohorts (seeFile S10 in
supporting information for full results). For every 1 year of difference
in education between SVD and control groups, the cognitive effect size
decreased (indicating superior performance of the control groups) by
an estimated 0.23 standard deviations in the domain of executive func-
tion (95% CI: –0.37, –0.09; P = .004), 0.28 standard deviations in the
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TABLE 4 Demographics of SVD cohorts with non-clinical presentations of SVD, stroke, or cognitive impairment/dementia
Non-clinical Stroke
Cognitive
impairment/dementia
% cohorts
(n= 32)
Mean (SD or
95%CI)
% cohorts
(n= 26)
Mean (SD
or 95%CI)
% cohorts
(n= 31)
Mean (SD or
95%CI)
Uncorrected
P valuec
Mean agea 100% 66.1 (62.8, 69.4) 96.2% 69.0 (67.0, 71.1) 100% 72.8 (70.9, 74.7) .002b
% female 71.9% 53.2 (20.8) 92.3% 42.0 (8.5) 93.5% 51.6 (14.6) .027
Mean years educationa 68.8% 10.6 (9.5, 11.7) 61.5% 10.6 (9.4, 11.8) 93.5% 9.9 (8.8, 10.9) .515
% hypertension 62.5% 60.3 (28.7) 65.4% 68.6 (17.6) 35.5% 75.1 (16.4) .214
% diabetes 59.4% 23.4 (16.4) 61.5% 28.6 (12.7) 32.3% 24.4 (9.1) .524
aMean age andmean years of educationwere calculated using random effects meta-analysis in themeta: An R package formeta-analysis. R News 2007, 7(3),
40–45.121 Only studies that presented group-level data for age and years of education asmean and standard deviationwere included in thesemeta-analyses.
bSignificant difference at P< .01 between non-clinical and cognitive impairment/dementia groups.
cP value refers to comparisonsmade by one-way analysis of variance.
Abbreviations: CI, confidence interval; SD, standard deviation; SVD, cerebral small vessel disease.
domain of visuospatial ability (95%CI: –0.46, –0.10; P= .009), and 0.31
standard deviations in the domain of language (95% CI: –0.46, –0.16;
P= .001). Including education as a predictor inmeta-regressionmodels
reduced I2 values by≈13% in the domain of visuospatial ability and lan-
guage, suggesting that educationmay account for some of the variabil-
ity in cognitive effect sizes in thesedomains.Overall, however, I2 values
remainedhigh. This could bedue toour use of group-level demographic
and vascular risk data, which may limit power to detect interactions
between individual-level covariates and cognitive effect sizes. Meta-
analytic approaches using individual patient data are increasingly pop-
ular but rely upon the availability of patient-level datasets, which in our
sample were rare.
The majority of the meta-regression models assessing the influ-
ence of age on cognitive effect size produced df < 4, suggesting that
model results were unreliable. Therefore, we further investigated the
potential influence of age by re-running meta-analysis models exclud-
ing studies in which SVD and control groups were not matched for
age. In these analyses magnitudes of estimated effect sizes were sim-
ilar to the initial meta-analysis models and all models remained signifi-
cant.Meta-regressionmodels investigating the impact of hypertension
and diabetes on cognitive effects also produced df < 4 suggesting that
model results were unreliable, likely due to the limited availability of
vascular risk data.
2.2.3 Study quality
Themean study quality scorewas 4.97 (median 5, range 2–8). Themag-
nitudes of estimated effect sizes were comparable to those using the
full meta-analysis dataset, and all models remained significant (see File
S11 in supporting information). I2 values reduced by a small amount in
the domains of executive function, visuospatial ability, attention, and
language, but increased in the other domains.
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